{"id":432889,"title":"Notice: Prescription Drug List (PDL): Multiple additions [2018-03-12] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-02","captureTimestamp":"2026-01-02T09:06:59.042000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-multiple-additions-20.html?wbdisable=true","snippet":"Notice: Prescription Drug List (PDL): Multiple additions March 12, 2018 Our file number: 18-102696-288 The purpose of this Notice of Amendment is to notify about the additions of avelumab, dupilumab, guselkumab, lifitegrast, lotilaner, olaratumab, sebelipase alfa, semaglutide,…","rawSnapshotUrl":"/api/snapshots/raw/432889","browseUrl":"https://replay.healtharchive.ca/job-6/20260102090659/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-multiple-additions-20.html?wbdisable=true#ha_snapshot=432889","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}